177lu-ab-3prgd2
PeptideexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2021 (NCT05013086)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 177-lutetium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06375564 | Phase 1 | Jun 12, 2024 | Xiamen University |
| NCT05013086 | Early Phase 1 (Phase 1) | Oct 1, 2021 | Chinese Academy of Medical Sciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Xiamen University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1